These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 25703303)

  • 41. A quantitative study on the expression of synapsin II and N-ethylmaleimide-sensitive fusion protein in schizophrenic patients.
    Imai C; Sugai T; Iritani S; Niizato K; Nakamura R; Makifuchi T; Kakita A; Takahashi H; Nawa H
    Neurosci Lett; 2001 Jun; 305(3):185-8. PubMed ID: 11403936
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Author Correction: A novel pathway regulates social hierarchy via lncRNA AtLAS and postsynaptic synapsin IIb.
    Ma M; Xiong W; Hu F; Deng MF; Huang X; Man HY; Lu Y; Liu D; Zhu LQ
    Cell Res; 2021 May; 31(5):601. PubMed ID: 33707743
    [No Abstract]   [Full Text] [Related]  

  • 43. Alterations in plasma vascular endothelial growth factor levels in patients with schizophrenia before and after treatment.
    Lee BH; Hong JP; Hwang JA; Ham BJ; Na KS; Kim WJ; Trigo J; Kim YK
    Psychiatry Res; 2015 Jul; 228(1):95-9. PubMed ID: 25977072
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Increased activity of frontal and limbic regions to emotional stimuli in children at-risk for anxiety disorders.
    Christensen R; Van Ameringen M; Hall G
    Psychiatry Res; 2015 Jul; 233(1):9-17. PubMed ID: 25978933
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PAOPA, a potent dopamine D2 receptor allosteric modulator, prevents and reverses behavioral and biochemical abnormalities in an amphetamine-sensitized preclinical animal model of schizophrenia.
    Beyaert MG; Daya RP; Dyck BA; Johnson RL; Mishra RK
    Eur Neuropsychopharmacol; 2013 Mar; 23(3):253-62. PubMed ID: 22658400
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Medial prefrontal cortical synapsin II knock-down induces behavioral abnormalities in the rat: examining synapsin II in the pathophysiology of schizophrenia.
    Dyck BA; Beyaert MG; Ferro MA; Mishra RK
    Schizophr Res; 2011 Aug; 130(1-3):250-9. PubMed ID: 21689907
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Effect of PAOPA, a Novel Allosteric Modulator of Dopamine D2 Receptors, on Signaling Proteins Following Sub-Chronic Administration in Rats.
    Daya R; Ho J; Thomson S; Bhandari J; Mishra RK
    Curr Mol Pharmacol; 2021 Oct; 14(4):469-476. PubMed ID: 32912130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Preclinical pharmacokinetic and toxicological evaluation of MIF-1 peptidomimetic, PAOPA: examining the pharmacology of a selective dopamine D2 receptor allosteric modulator for the treatment of schizophrenia.
    Tan ML; Basu D; Kwiecien JM; Johnson RL; Mishra RK
    Peptides; 2013 Apr; 42():89-96. PubMed ID: 23416534
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Dopamine D2 heteroreceptor complexes and their receptor-receptor interactions in ventral striatum: novel targets for antipsychotic drugs.
    Fuxe K; Borroto-Escuela DO; Tarakanov AO; Romero-Fernandez W; Ferraro L; Tanganelli S; Perez-Alea M; Di Palma M; Agnati LF
    Prog Brain Res; 2014; 211():113-39. PubMed ID: 24968778
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Change in expression of vesicular protein synapsin II by chronic treatment with D2 allosteric modulator PAOPA.
    Basu D; Tian Y; Hui P; Bhandari J; Johnson RL; Mishra RK
    Peptides; 2015 Apr; 66():58-62. PubMed ID: 25703303
    [TBL] [Abstract][Full Text] [Related]  

  • 52.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 53.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 54.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 55.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 56.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 57.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]     [New Search]
    of 3.